Science and Research

A Phase I, Multicenter, Open-Label, Multiple Ascending Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS135 Added to Background Pulmonary Arterial Hypertension (PAH) Therapy

To assess the safety and tolerability of 24 weeks of HS135 SC therapy in patients with PAH.

Study details
Study-ID: 2023-510452-23-00
Study-ID: 2023-510452-23-00
DZL Disease Area: PH
DZL Disease Area: PH
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BREATH
DZL Participating Sites: BREATH
Start Date: 24.10.2024
Completion Date: 31.12.2026
Status: Recruiting
Status: Recruiting
DZL recruiting center, DZL on steering board


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.